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Abstract
IL-24, a member of the IL-10 family of cytokines, is produced by monocytes and Th2 cells. Interestingly, immune cells do not appear
to express specific IL-24 receptor chains (IL-20R1/IL-20R2 and IL-22R/IL-20R2), it is therefore unlikely that IL-24 has classical
immune-modulating properties. Skin, on the other hand, seems to represent a major target tissue for IL-24 and related cytokines such
as IL-19, -20, and -22. However, the initial interest in IL-24 did not arise from its physiological signalling properties through its cognate
receptors but rather because of its tentative ability to selectively kill different cancer cells. In an attempt to further investigate the sig-
nalling events underlying the IL-24-induced cancer cell death, we found that melanoma cell lines did not react in the expected and pre-
viously described way. Using several different forms and delivery modes of IL-24, we were unable to detect any apoptosis-inducing
properties of this cytokine in melanoma cells. In the present ‘Point of view’ we will briefly summarizse these findings and put them in
context of published reports stating that IL-24 might be a long sought after treatment for several types of cancer.
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Background
Soon after its discovery in 1995, IL-24 (then called mda-7) has
been described as a potential therapeutic option for cancer
(reviewed in [1–4]). First thought to be a tumour suppressor,
Zhang et al. [5] clarified already in 2000 that mda-7/IL-24 is in fact
a secreted protein, further substantiated by the identification of the
specific receptor complexes [6, 7], which led to the re-naming of
mda-7 to IL-24 cytokine. Nevertheless, around 100 publications,
the majority of which come from three groups at Columbia
University, the M.D. Anderson Cancer Center in Texas and Introgen
Therapeutics, have suggested that IL-24 has the ability to selec-
tively and efficiently kill cancer cells in vitro and in vivo. These
astonishing properties led to the rapid development of a therapeu-
tic regimen by which a modified adenovirus delivers IL-24 to can-
cer patients (INGN-241, Introgen Therapeutics, Inc., Houston, TX,
USA). Initial results of clinical trials, which commenced in the year
2000, were released in 2004. Although these reports claimed low
toxicity in preclinical and phase 1 studies [8] and some efficacy in
malignant melanoma therapy in a phase 2 trial [9], further reports
on clinical developments around IL-24 are lacking thus far.
According to information released on Introgens’ homepage
(www.introgen.com), INGN-241 is still being tested in a phase 3
clinical study in head and neck cancer patients as well as in phase
2 studies in melanoma and other solid tumours. After the comple-
tion of these trials, it will have to be evaluated whether IL-24,
delivered by a modified and replication-incompetent adenovirus
(INGN-241) can live up to the high expectations that have been
raised in the past [2, 3, 10].
IL-24: a normal cytokine?
IL-24, together with IL-10, -19, -20, -22, -26, -28, and -29, are
members of the group of IL-10-like cytokines. IL-19, IL-20, IL-22,
and IL-24 have been proposed to form a unique IL-19 subfamily
characterized by their structural features and aggregation state as
monomers [11–13]. Although sequence homologies within this
group do not exceed 25%, there is some conservation of structural
features, namely the presence of six to seven -helices in all family
members [11, 13, 14]. Another common denominator of this
group is the sharing of receptor chains, best exemplified by IL-24
and IL-20, which can both bind to the same two receptor complexes:
© 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd 
doi:10.1111/j.1582-4934.2008.00372.x
Point of View
*Correspondence to: Stephanie KREIS,
Life Sciences Research Unit,
University of Luxembourg,




IL-20R1/IL-20R2 and/or IL-22R/IL-20R2 [6]. The biological func-
tions and structural characteristics of individual members of the
IL-10-like cytokine group have been reviewed in more detail else-
where [11, 13–15]. In brief, physiological properties that involve
engagement of the respective receptor complexes and subsequent
signalling through the Jak/STAT pathway, range from triggering
anti-inflammatory responses (IL-10) and possibly antiviral
responses (IL-28, and -29) to pro-inflammatory reactions (IL-22).
Functions of IL-19, -20, and -24 are less well defined but several
reports indicate pro-inflammatory [16] roles in diseased skin,
which is the major target tissue for these cytokines [14, 17–20].
In this context, it has recently been shown by microarray analysis
on human keratinocytes that IL -24 similar to the other IL-10-like
cytokines up-regulates a set of inflammatory and immune-
modulating genes that is characteristic of expression patterns
seen in psioriatic skin lesions [21]. Together with elevated expres-
sion levels of IL-19, -20, -22, and IL-24 in psoriasis [22], this indi-
cates that these cytokines may play an important role in the 
proliferation and differentiation of keratinocytes suggestive of an
involvement in the immunopathology of psoriasis and other
inflammatory skin diseases. Taken together, accumulating evidence
is pointing towards a physiological role of IL-24 (and related
cytokines) in the regulation of immune and inflammatory responses
of skin tissue.
IL-24: a potential cure for cancer?
IL-24 has been discovered by subtraction hybridization, a method
that involves the reversal of de-differentiated cancer-like growth
characteristics by treatment of cells with IFN- and a protein
kinase C activator [23]. Compared to untreated melanoma cells,
genes that were up-regulated during the reversal phase towards a
more benign growth behaviour were hoped to play an active role
in preventing or stopping cancer cells from outgrowing their
healthy counterparts [24–26]. One of the candidates found to be
augmented during enforced terminal differentiation of melanoma
cells was IL-24, then called mda-7 (melanoma differentiation anti-
gen 7). Shortly after its discovery, two lines of evidence suggested
that IL-24 may indeed be a promising cytokine to be studied fur-
ther as a cancer therapeutic agent. First, IL-24 reduced colony
numbers when transiently transfected into melanoma cells while
healthy cells remained unaffected by such a treatment [23, 27]
and secondly, IL-24 was found to be down-regulated with pro-
gression of melanomas in vivo [25]. This study, however, solely
relied on immunohistochemistry for scoring IL-24 expression,
and to our knowledge, it has remained the only report thus far
showing in vivo down-regulation of IL-24 with progression of can-
cer. The down-regulation of a gene with cancer progression
together with properties such as loss of heterozygosity (LOH) and
germline mutations, would make IL-24 a tumour suppressor
gene. However, Wang and Liang have already clarified in 2003
[28] that there is no convincing evidence to this day for IL-24 to
be considered a tumour suppressor.
Despite the already mentioned advanced stages of clinical test-
ing, many fundamental questions regarding the physiological and
‘supra-physiological’ properties of IL-24 remain open or contro-
versial. For instance, conflicting data regarding IL-24 produced
from stably transfected Hek cells exist. Some reports claim that
Hek-IL-24 efficiently kills cancer cells [29–32] while others were
unable to alter the growth characteristics of cancer cells with Hek-
IL-24 [33–35]. Similarly, opposing data can also be found con-
cerning the ability of bacterially expressed GST-IL-24 to drive can-
cer cells into apoptosis. Some studies reported that GST-IL-24 can
kill prostate, breast, renal, and pancreatic cancer cell lines [36–38]
while we and others have not detected these effects of bacterially
expressed IL-24 [33, 39, 40]. Another enigma around IL-24 is its
ability to distinguish between healthy and cancer cells. How differ-
ent forms of recombinant IL-24 can reliably differentiate between
a normal and a cancer cell remains completely elusive. Finally, IL-
24 secreted from cancer cells infected with an adenovirus encod-
ing IL-24 has been described to bind to receptors on neighbour-
ing cells. On surrounding non-cancer cells, this interaction acti-
vates the Jak/STAT pathway without any cytotoxic effects. On
receptor-positive cancer cells, however, the binding of IL-24 trig-
gered apoptosis of melanoma and other cancer cells, independent
of Jak/STAT signalling, an effect that which has been termed
‘bystander effect’ [10, 39]. Taken together, IL-24 has been sug-
gested to distinguish between cancer and normal cells and by
doing so it can kill the cancer cells in a receptor-independent or -
dependent fashion, either through direct interaction or via second-
ary bystander effects, respectively. In this context, we recently
found that the melanoma cell lines used in the above study
(Wm35, Mewo, and A375) [39] hardly expressed IL-24 receptors
and consequently did not show phosphorylation of STAT3 follow-
ing IL-24 treatment [33]. Hence, the receptor-mediated killing of
these cells by IL-24 or possible bystander effects are difficult to
reconcile with the fact that sufficient amounts of the three possi-
ble receptor chains were not present on such cells. In the same
study, we further investigated different forms and modes of IL-24
delivery to melanoma cells but could not identify any condition
under which this cytokine killed melanoma cells [33]. To substan-
tiate our data, we have used four different ways of treating a panel
of melanoma cell lines with IL-24: (1) by GST-IL-24 fusion protein
(previously shown to kill cancer cells [36]); (2) by IL-24 secreted
from transfected Hek cells, also previously published to drive can-
cer cells selectively and efficiently into apoptosis [39]. Thirdly, we
have used intracellular over-expression, as we reckoned that a
higher threshold amount of IL-24 might be necessary to trigger
the unfolded protein response (UPR) pathway, which drives target
cells into apoptosis [41] and finally, we have applied various
amounts of commercial IL-24. None of the above forms and deliv-
ery regimens killed cancer cells more than appropriate control
treatments. Taken together, we neither saw a selective ability of IL-
24 itself to distinguish between healthy and cancer cells, nor did
we detect IL-24-induced killing of melanoma cells. Therefore, we
assume that only the combination of IL-24 with an adenoviral
backbone might have the beneficial and desired selective cancer
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killing effects. (Fig. 1) illustrates and summarizes the effects 
that the described different forms and delivery modes of IL-24
might have.
Adenovirus: contributions to IL-24 
oncolytic effects?
In order to improve IL-24 delivery to cancer cells, various replication-
deficient adenoviruses have been developed that all aim at selectively
transducing target cells. Third generation adenoviruses driven by
promoters, which only function in cancer cells have boosted the
selectivity of IL-24 delivery even further [42, 43]. Over the past
decade, many studies have claimed that intracellular over-expression
of an adenovirus encoded IL-24 (Ad-IL-24) drives a multitude of dif-
ferent cancer cells and types into apoptosis or regression, respec-
tively. There is evidence that the combination of IL-24 with an aden-
oviral backbone has the desired oncolytic effects while the empty vec-
tor control does not [44–46], however, a useful but still lacking con-
trol for the specificity of IL-24 and for synergistic effects of the Ad
backbone would be an adenovirus expressing IL-20, as IL-20 is a
related cytokine that uses the same receptor complexes.
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Fig. 1 Summary of possible IL-24-induced effects. The figure depicts schematically our view of the effects that different sources and delivery modes
of IL-24 can have on receptor-positive or -negative cells. The left side of the scheme shows receptor-mediated activation of the Jak/STAT pathway and
subsequent regulation of STAT target genes on receptor-positive (IL-20R1/IL-20R2 and/or IL-22R/IL-20R2) cells by different forms of IL-24: 1. human
IL-24: human endogenous IL-24, 2. Hek-IL-24: human IL-24 expressed from Hek cells, 3. mouse IL-24: commercially available human IL-24
expressed from mouse cells. On the right- hand side receptor-independent effects are shown: 4. GST-IL-24: recombinant fusion protein expressed
from bacteria, 5. plasmid IL-24: plasmid-encoded IL-24, over-expressed following nucleofection, 6. Ad-IL-24: IL-24, with or without signal peptide,
transduced by modified adenoviruses. Only IL-24 in combination with an adenoviral expression backbone may kill target melanoma or other cancer
cells while intracellular overexpression of IL-24 or any other kind of IL-24 on its own does not lead to increased cell death. In this context, we have
recently shown the lack of apoptosis-inducing effects of different forms of IL-24 (light blue box, no. 2–5) on melanoma cells.
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